Bio Medica Laboratories IPO
Upcoming SMEAlready have an account? Apply now
Bio Medica Laboratories IPO details
Schedule of Bio Medica Laboratories
| Issue open date | 21 May 2026 |
| Issue close date | 25 May 2026 |
| UPI mandate deadline | 25 May 2026 (5 PM) |
| Allotment finalization | 26 May 2026 |
| Refund initiation | 27 May 2026 |
| Share credit | 27 May 2026 |
| Listing date | 29 May 2026 |
| Mandate end date | 09 Jun 2026 |
| Lock-in end date for anchor investors (50%) | 24 Jun 2026 |
| Lock-in end date for anchor investors (remaining) | 23 Aug 2026 |
Note: The schedule is tentative. The anchor lock-in period ends 30 days after the actual allotment date for 50% of the shares and 90 days after for the remaining portion. The allotment status can be checked on the registrar's website and the exchange website.
About Bio Medica Laboratories
Bio Medica Laboratories Limited is a pharmaceutical company engaged in the manufacturing of pharmaceutical parenteral formulations. The company manufactures generic injectable drugs, including liquid injections and dry powder injections, for both human and veterinary use. Its products are offered in single-dose and multi-dose formats to address a range of medical requirements. The company follows a business-to-business (B2B) model and primarily generates revenue through contract manufacturing arrangements with pharmaceutical companies. Under this model, Bio Medica manufactures formulations based on customer specifications, while the client company markets the products under its own brand name or as a technical collaborator. The company operates manufacturing facilities in Indore, Madhya Pradesh, and focuses on supplying formulations to other pharmaceutical businesses rather than directly selling to end consumers.
Financials of Bio Medica Laboratories
Issue size
| Funds Raised in the IPO | Amount |
| Total issue size | 52.43 |
| Fresh Issue – Proceeds go to the company | 47.19 |
| Offer for sale – Proceeds go to the existing investors | 5.24 |
Utilisation of proceeds
| Purpose | INR crores (%) |
| Repayment of borrowings | 6.5 (13.77%) |
| New manufacturing facility at existing premises | 28.5 (60.39%) |
| General corporate purposes | 12.19 (25.84%) |
Strengths
- Bio Medica manufactures generic injectable drugs for both human and veterinary use.
- The company operates on a B2B contract manufacturing model with pharmaceutical companies.
- Promoters have over 18 years of experience in the pharmaceutical sector.
- The company offers liquid injections and dry powder injections in single and multi-dose formats.
- Revenue and profitability improved significantly in FY25 compared to previous years.
Risks
- Production at Manufacturing Unit-I was suspended due to regulatory non-compliances.
- The company operates from leased properties and does not own its manufacturing premises.
- The business may face conflicts of interest with promoter group entities in similar businesses.
- The company had a high debt-to-equity ratio in previous financial years.
- Failure to renew or maintain licenses and approvals could affect operations.